dermatologyadvisor9d
FDA Alert: Pulmonology Drug Approvals, Recalls, and Device Updates
FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.
PharmiWeb9d
FDA approves Roche’s Susvimo as the first and only continuous delivery treatment for the leading cause of diabetes-related blindness
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL for the treatment of diabetic macular edema ...
C&EN22d
50 new drugs received FDA approval in 2024
C&EN’s tabulation follows approvals from the FDA’s Center for Drug Evaluation and Research; therefore, it does not include blood products, gene therapies, vaccines, and other therapies that ...
NBC News22d
Federal regulations paused, halting FDA's proposed ban on formaldehyde in hair products
The Food and Drug Administration announced it would decide by April 2024 whether chemical hair straightening products sold in the U.S. would be banned from using formaldehyde or ingredients that ...
Cancer Therapy Advisor23d
FDA Approves Datroway for Advanced HR+, HER2- Breast Cancer
The approval was based on data from the phase 3 TROPION-Breast01 trial. The US Food and Drug Administration (FDA) has approved Datroway (datopotamab deruxtecan-dlnk) for the treatment of adults ...
Newsweek23d
FDA Approves Nasal Spray for Depression
The nasal spray Spravato, which is made from the drug esketamine, had been approved in 2019 for patients who failed to respond to at least two oral antidepressants. However, it had to be used in ...
CNN23d
FDA approves standalone use of J&J’s ketamine-derived depression treatment
The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe depression ...
Popular Science23d
FDA approves first-of-its-kind nasal spray for severe depression
Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD ...
UPI23d
FDA approves Spravato, first monotherapy nasal spray to treat depression
Jan. 21 (UPI) --The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression. Johnson & Johnson's Spravato has been approved to treat a ...
UVA Today24d
FDA Bans Red Dye No. 3 in Food, Decades After Banning It in Cosmetics
The U.S. Food and Drug Administration has banned the use of red dye No. 3 in foods, more than three decades after researchers discovered its link to cancer in rodents and to worsened attention deficit ...
Reuters24d
FDA approves standalone use of J&J's ketamine-derived depression treatment
Jan 21 (Reuters) - The U.S. Food and Drug Administration expanded approval for Johnson & Johnson's (JNJ.N), opens new tab nasal spray, Spravato, to allow it to be used as a standalone treatment ...